Abstract
Zonisamide has been used as an add-on treatment in order to overcome the deficiencies of the general therapies currently used to resolve the motor complications and non-motor symptoms of Parkinson disease. Various trials have been designed to investigate the mechanism of action and treatment effects of zonisamide in this condition. Most clinical trials of zonisamide in Parkinson disease were from Japan. The vast majority of studies used changes in the Unified Parkinson’s Disease Rating Scale (UPDRS) scores and daily “OFF” time as primary endpoints. Based on adequate randomized controlled trials, zonisamide is considered a safe and efficacious add-on treatment in Parkinson disease. The most convincing proof is available for a dosage of 25–50 mg, which was shown to lead to a significant reduction in the UPDRS III score and daily “OFF” time, without increasing disabling dyskinesia. Furthermore, zonisamide may play a beneficial role in improving non-motor symptoms in PD, including impulsive–compulsive disorder, rapid eye movement sleep behavior disorder, and dementia. Among the various mechanisms reported, inhibition of monoamine oxidase-B, blocking of T-type calcium channels, modulation of the levodopa–dopamine metabolism, modulation of receptor expression, and neuroprotection are the most often cited. The mechanisms underlying neuroprotection, including modulation of dopamine turnover, induction of neurotrophic factor expression, inhibition of oxidative stress and apoptosis, inhibition of neuroinflammation, modulation of synaptic transmission, and modulation of gene expression, have been most extensively studied. This review focuses on structure, pharmacokinetics, mechanisms, therapeutic effectiveness, and safety and tolerability of zonisamide in patients with Parkinson disease.
Introduction
After Alzheimer disease, Parkinson disease (PD) is the most prevalent neurodegenerative disorder (; Yang and Perry, 2009). The primary pathological manifestation of PD is the reduction of dopamine-producing cells in the nigrostriatal pathway, which causes a significant reduction in the dopamine levels of the striatal cells (; Liu et al., 2020). However, the etiology of and the mechanisms underlying the decrease in dopaminergic neurons remain unclear. At the moment, dopamine replacement drugs, such as dopamine agonists and levodopa, are generally efficacious in PD patients (). Nevertheless, the effectiveness of levodopa and dopamine agonists is gradually lost, and disabling motor complications worsen as time passes, as the current drugs do not slow or halt the progression of neurodegeneration (; Lew, 2007). Non-motor symptoms also appear and threaten patients’ quality of life as the disease progresses (Schapira, 2007). Therefore, there remains a need for new therapeutic strategies (Miwa, 2007). Zonisamide (ZNS) may be an effective therapeutic agent, with varied mechanisms of action relevant to the treatment of PD.
ZNS is a sulfonamide developed in Japan (Uno et al., 1979; Murata, 2004; ). It has been approved for the treatment of seizures in Japan since 1989 and is commercially available worldwide (Miwa, 2007). Thereafter, ZNS has been authorized as an add-on treatment, along with levodopa, for PD patients in Japan since 2009 (Yang and Perry, 2009). In 2000, Murata et al. (2001) serendipitously discovered that ZNS was efficacious for both epileptic seizures and Parkinsonian symptoms in a single patient. Since then, dozens of preclinical and clinical studies have been performed to clarify the mechanisms and therapeutic effectiveness of ZNS, and the related research has progressed rapidly over the last 10 years. Since the last review was published in 2013 (), there has been a need to summarize the studies reported in the interim. This review focuses on the structure, pharmacokinetics, mechanisms, therapeutic effectiveness, and safety and tolerability of ZNS in patients with PD.
Structure
ZNS is a sulfonamide drug (Uno et al., 1979). Its chemical name is 1,2-benzisoxazole-3-methanesulfonamide, and molecular weight is 212.227 g/mol. The chemical structure of ZNS is shown in Figure 1.
FIGURE 1
Pharmacokinetics
The pharmacokinetics of ZNS has been well investigated and summarized previously (Sills and Brodie, 2007; Yang and Perry, 2009) and are shown in Table 1, based on preclinical or clinical trials, prescribing information, and previous reviews (Ito et al., 1982; Matsumoto et al., 1983; Miwa, 2007; ).
TABLE 1
| Zonisamide | |
| Alternative names | AD-810, ZonegranR |
| ATC code | N03A (antiepileptic drugs), N04 (antiparkinsonian drugs) |
| Mechanisms | See Figure 2 |
| Prescription | |
| Route | Orally |
| Recommended dosage | 25, 50 mg |
| Administration mode | Once daily |
| Indication | |
| Recommended as add-on treatment in patients with Parkinson disease | |
| Pharmacokinetics (Uno et al., 1979; Ito et al., 1982; Matsumoto et al., 1983; Stiff et al., 1992; Nakasa et al., 1998; Ohmori et al., 1998; Sills and Brodie, 2007; Yang and Perry, 2009) | |
| Mean maximum plasma concentration (Cmax) | 2.3–12 mg/ml |
| Median time (tmax) | 2.4–3.6 h |
| Absolute bioavailability | Nearly 100% |
| Apparent volume of distribution | 1.1–1.7 L/kg |
| Clearance | 1.91 L/h |
| Elimination half-life | 49.7–62.5 h |
| Pivotal trials | See Table 2 |
| Common adverse events | See Table 3 |
Properties of zonisamide.
ATC, Anatomical Therapeutic Chemical.
It has been demonstrated that the P450 enzyme CYP3A4 is primarily responsible for the metabolism of ZNS, whereas CYP3A5 and CYP2C19 may also be involved (Nakasa et al., 1998; Ohmori et al., 1998; Morita et al., 2005). All ZNS derivatives, including 2-sulfamoylacetylphenol, N-acetyl ZNS, and unaltered ZNS, are excreted in the urine and feces (Stiff et al., 1992). Notably, potential interactions between ZNS and other medications for PD also need to be taken into account (Sills and Brodie, 2007; ).
Mechanisms of Action
The antiparkinsonian mechanism of ZNS is complicated. As the treatment dosage of ZNS in PD is 25–50 mg/day, which is markedly lower than that for the treatment of epilepsy (200–400 mg/day), the mechanism involved is likely to be different (Murata et al., 2007). Here, we will review possible mechanisms, with a particular focus on advances in the last several years, involving both dopaminergic and non-dopaminergic mechanisms.
Inhibition of Monoamine Oxidase-B
ZNS is capable of inhibiting monoamine oxidase-B (MAO-B) (Uemura et al., 2017). Sonsalla et al. (2010) reported that ZNS regulates MAO-B activity, reversibly, with an IC50 of 25 μM in vitro.
Previous studies have demonstrated that the metabolism of dopamine by MAO-B produces reactive oxygen species (ROS), which contribute to nigrostriatal degeneration (). ZNS prevents the formation of 1-methyl-4-phenylpyridinium [MPP(+)], which is derived from 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) via MAO-B, and thereby inhibits the oxidation of dopamine to hydrogen peroxide and the related neurotoxic effects (Siebert et al., 2000; Sonsalla et al., 2010).
Blocking of T-Type Calcium Channels
Previous experimental studies have suggested that patterns of neural firing activity in the basal nuclei in MPTP-induced mice or PD patients are switched to a bursting discharge pattern (Wang et al., 2006; Wichmann and DeLong, 2006; ). This activity could be reduced by ZNS as this drug blocks the voltage-gated Na+ channels and voltage-gated Ca2+ channels (T-type calcium channels), resulting in improvement in PD symptoms (Yang et al., 2014; Kunisawa et al., 2018). Additionally, Yurekli et al. (2013) demonstrated that ZNS decreased the level of cytosolic free Ca2+ in an MPP-induced neuronal cell model of PD.
Modulation of Levodopa-Dopamine Metabolism
Nishijima et al. (2018) demonstrated that the effect of ZNS is primarily due to the modulation of levodopa-dopamine metabolism in the striatum. They found that levodopa-induced dyskinesia (LID) was significantly enhanced by prescription of ZNS. On the contrary, apomorphine-induced dyskinesia was not affected by prescription of ZNS. ZNS may enhance dopamine synthesis (Miwa, 2007). ZNS increases the intracellular dopamine concentration when the drug is administered at 25 or 50 mg/kg daily for 3 weeks (Okada et al., 1995). Murata et al. (Murata, 2004) demonstrated that enhanced expression of tyrosine hydroxylase (TH) mRNA contributed to increased dopamine synthesis. They found that levels of TH mRNA were increased in the rat striatum when ZNS was administered at 20 or 50 mg/kg daily for 2 weeks. However, Nishijima et al. (2018) found that a single administration of ZNS did not induce dyskinesia, and TH was not involved in levodopa metabolism. Thus, the enhanced expression of TH cannot fully explain the increased levodopa effect. Further studies are required to demonstrate this mechanism.
It has also been reported that ZNS increases the extracellular dopamine concentration, suggesting that suppression of dopamine reuptake may explain the increased extracellular dopamine concentration (Nishijima et al., 2018). It has been reported that ZNS could increase the release of dopamine (; Miwa, 2007). However, a recent study showed that ZNS could not elevate striatal expression of vesicular monoamine transferase-2 and dopamine decarboxylase by Western blot analyses, suggesting that it may not be the main mechanism underlying the antiparkinsonian effects of ZNS (Nishijima et al., 2018).
Modulation of Receptor Expression
Recently, Oki et al. (2017) reported that ZNS could ameliorate LID by modulating the expression of receptors. They designed different models of levodopa-ZNS administration in four groups, namely, intermittent ZNS and levodopa injection, intermittent levodopa injection, continuous levodopa infusion, and no medication. Two weeks after the treatment, they analyzed the mRNA expression of endocannabinoid CB1 receptor, D1 and D2 receptors, and adenosine A2A receptor in the striatum of PD model rats in each group. Their results indicated that intermittent prescription of levodopa induced LID, which was related to the upregulation of dopamine D1 and adenosine A2A receptors. ZNS injection improved LID by downregulation of adenosine A2A and endocannabinoid CB1 receptors.
Neuroprotection
It has been reported that ZNS could inhibit the reduction of dopamine-producing cells in neurotoxin-induced animal models of PD (Willmore, 2005; Rosler et al., 2010; Sonsalla et al., 2010; Ikeda et al., 2018). There are indeed a growing number of studies that have explored its neuroprotective effects (; Santos, 2012). Below, we review the possible mechanisms. A diagrammatic illustration of the neuroprotective mechanisms of ZNS is shown in Figure 2.
FIGURE 2
Modulation of Dopamine Turnover
, reported that ZNS protected dopamine-producing cells in MPTP-treated models of PD, which may be related to increased S100beta secretion by astrocytes. ZNS also increased dopamine turnover, as surviving dopaminergic neurons recovered the production of dopamine after ZNS prescription (). Yokoyama et al. (2010) reported that treatment with ZNS significantly prevented the dopaminergic neuronal damage and proliferation of microglia and increased TH protein levels. Furthermore, they found that ZNS significantly attenuated the motor syndrome a week after MPTP treatment in the behavioral study. Additionally, Ikeda et al. (2018) demonstrated that ZNS treatment delayed the reduction of striatal presynaptic dopamine transporter levels, suggesting that ZNS may play an essential role in slowing the deterioration of early stage PD. They examined the average specific binding ratio (SBR) of dopamine by dopamine transporter single-photon emission computed tomography at the baseline. The SBR decline rate was significantly reduced in the ZNS group, whereas the SBR was significantly reduced in the placebo at the endpoint.
Notably, Yano et al. (2009) mentioned that ZNS could prevent MPTP-induced increases in the levels of glial fibrillary acidic protein in striatal neurons, but came to the opposite conclusion. Further studies are needed to resolve this contradiction.
Induction of Neurotrophic Factors
Sano et al. (2015) reported that ZNS could reduce the death of nigrostriatal dopamine-producing neurons via signal transduction by neurotrophic factors. There were increased levels of brain-derived neurotrophic factors in the substantia nigra and striatum in the ZNS group compared with placebo. found that ZNS increased the expression of neurotrophic factors in astrocytes.
An experimental study has reported that ZNS could enhance neurite elongation after nerve injury in primary motor neurons in vitro (Yagi et al., 2015). They also found that ZNS could enhance neurite regeneration and protect primary motor neurons against oxidative stress by inducing increased expression of neurotrophic factors (neurotrophin-4/5, brain-derived neurotrophic factors, and nerve growth factors) and their receptors. Further studies are needed to demonstrate whether ZNS has similar effects in nigrostriatal dopaminergic cells.
Inhibition of Oxidative Stress and Apoptosis
Some findings have suggested that ZNS exerts neuroprotective effects mainly via antioxidant action. Ueno et al. (2018) reported that long-chain acylcarnitine (LCAC) levels were raised in PD patients after ZNS treatment. As an increase in LCACs implies improvement in mitochondrial beta-oxidation, ZNS may have antioxidant properties. reported that ZNS could reduce intracellular ROS levels and restore mitochondrial membrane potential. found that ZNS could protect the striatum against irreversible mitochondrial impairment through a γ-aminobutyric acid (GABA)–mediated mechanism. and Kawajiri et al. (2010) reported that ZNS could increase levels of manganese/copper/zinc superoxide dismutase (Mn/Cu/Zn-SOD) in astrocytes. Yurekli et al. (2013) demonstrated that ZNS could induce modulating effects that increased glutathione (GSH) and glutathione peroxidase levels. Concentrations of cytosolic free Ca2+ and lipid peroxidation were also lower in ZNS treatment groups (Yurekli et al., 2013; Ueno et al., 2018). , found that ZNS prevented levodopa-induced dopamine quinone formation in the striatum. They also found that ZNS treatment significantly increased GSH levels by enhancing the expression of cystine/glutamate exchange transporter (xCT). However, reached the opposite conclusion. In their experiments, ZNS did not alter GSH levels or influence the expression of xCT both in vivo and in vitro. More experiments are needed to resolve the contradiction. Moreover, ZNS exerted antiapoptotic effects, as demonstrated by increased cell viability and attenuated caspase-3 activity in human neuroblastoma (SH-SY5Y) cells (Kawajiri et al., 2010; ).Tsujii et al. (2015a,b) reported that ZNS had neuroprotective effects against endoplasmic reticulum (ER) stress. ZNS inhibited SH-SY5Y cell death in vitro and suppressed ER stress–related cell death in vivo via inhibiting the expression of ER stress–induced factors. Furthermore, ZNS suppressed ER stress–related neuron death by inhibiting caspase-3 activation (Yurekli et al., 2013; Tsujii et al., 2015b). Omura et al. (2012, 2013) reported that ZNS inhibited caspase-3 activation via increases in HMG-CoA reductase degradation 1 protein levels. These studies demonstrated that inhibition of ER stress, especially the mechanism via caspase-3, was involved in the neuroprotective actions of ZNS.
Inhibition of Neuroinflammation
reported that ZNS may potentially modify the disease by inhibition of microglial voltage-gated sodium channels 1.6 (Nav1.6), as well as neuroinflammation. Nav1.6 is expressed in microglial cells of MPTP-induced PD mice and postmortem PD brains, and it contributes to neuroinflammation. ZNS also inhibited the MPTP-induced expression of tumor necrosis factor α and gp91 (phox). Together, these findings suggest that ZNS can reduce neuroinflammation and has neuroprotective potential.
Modulation of Synaptic Transmission
It is also possible that ZNS has an effect on synaptic transmission. Experimental studies have suggested that ZNS affects synaptic transmission related to the kynurenine pathway in astroglia (). ZNS could increase the release of metabotropic glutamate-receptor (mGluR) agonists from astrocytes, and activated mGluR agonists inhibited neurotransmission in both direct and indirect pathways, which may explain the efficacy and tolerability of ZNS in PD (; ; ). Yamamura et al. (2009) found that ZNS could influence the level of extracellular neurotransmitters in a dose-dependent manner. Striatal perfusion of ZNS increased the extracellular levels of dopamine in striatal cells and attenuated extracellular levels of GABA in both the subthalamic nucleus and globus pallidus. Extracellular levels of glutamate in the substantia nigra pars reticulata (SNr) were also decreased. Furthermore, they demonstrated that ZNS inhibited the indirect pathways of movement. Sano and Nambu (2019) examined neuronal activities in the SNr and found that ZNS administration showed longer inhibition and reduced late excitation, which suggested that ZNS may enhance the direct pathway, while inhibiting the indirect pathway (Tachibana et al., 2008; Sano et al., 2013).
Modulation of Gene Expression
demonstrated that ZNS had neuroprotective effects in a genetic model of PD by attenuating A53T α-synuclein–induced neurotoxicity. They found that ZNS could prevent the loss of dopamine-producing cells by inhibiting a cell death pathway or cellular damage caused by α-synuclein. Furthermore, Ueda et al. (2012) found that ZNS upregulated the expression of several genes associated with nervous system function and development, such as Gpr143 and Bdnf, and of some genes associated with metabolism, including Aldh1a7, Akr1b7, Dhdh, and Agmat. Moreover, ZNS downregulated the expression of a few genes associated with inflammation and the immune system.
Recently, identified a ZNS-responsive gene in PD patients. Carriers of mouse double-minute 4 (MDM4) gene had higher ZNS sensitivity, improved motor fluctuation, and reduced “OFF” time. Inhibition of p53 is associated with upregulation of MDM4. The association between higher MDM4 expression and “OFF” time reduction suggested that p53 downregulation may prevent the reduction of dopamine-producing cells and deterioration of PD.
Other Possible Mechanisms
Recently, some studies have investigated cell replacement therapy using induced pluripotent stem cells (iPSCs) for the treatment of PD (; Olanow et al., 2003; Mendez et al., 2005; ; Rhee et al., 2011). Yoshikawa et al. (2013) reported that ZNS administration improved the survival and differentiation of iPSC-derived dopaminergic neuronal in murine brains. ZNS improved the efficacy of cell replacement therapy for treating PD. Indeed, cell replacement therapy using iPSCs might be a novel therapy strategy for PD in the future.
Clinical Effectiveness of Zonisamide
Murata et al. (2001) incidentally found that ZNS was effective in treating PD patients. Since then, several clinical trials have been performed to explore the effectiveness of ZNS for the treatment of PD. Based on adequate randomized controlled trials (RCTs), ZNS is efficacious and safe as an adjunctive therapy in patients with PD (Janszky, 2009; Matsunaga et al., 2017). Additionally, the 2018 guideline has supported the use of ZNS for motor symptoms, especially for treating motor fluctuations (). We review the clinical trials below; further details are summarized in Table 2.
TABLE 2
| Type | Authors (year) | Phase | Length of trial | Enrolled/completed (%) | Inclusion/exclusion criteria | Dosage | Endpoints | Results |
| Open-label trial | Phase 2 | 3 months | 10/10 (100%) | H-Y stage I or II Untreated (De Novo) patients | 25 mg/day for 1 month and 50 mg/day for the next 2 months | UPDRS I-IV Tremor-related UPDRS (items 16, 20, and 21) Sleep condition | I.UPDRS III and tremor-related scores: markedly decreased (P < 0.01) II. Sleep state: improved markedly in 3 patients with RBD | |
| Open-label trial | Murata et al. (2001) | Phase 2 | 12 weeks | 9/9 (100%) | Advanced-PD patients | 50–200 mg/day | UPDRS I-IV (ON and OFF) H-Y stage (ON and OFF) “OFF” time | I. UPDRS II (OFF): clearly diminished (22.3–12.3, P < 0.001) II. H-Y stage (OFF): clearly improved (3.8–2.8, P < 0.01) III. “OFF” time: significant decreased (5.9–1.2 h, P < 0.001) |
| Double-blind RCT | Murata et al. (2007) | Phase 2/3b | UP to 16 weeks, including a 2 week run-in period | 347/279 (80.4%) | Advanced-PD patients | 25, 50, 100 mg/day or placebo | Primary: Variation in UPDRS III Others: Variation in the percentage of patients with ≥ 30% reduction in UPDRS III (responders) Variation in “OFF” time | I. ZNS 25–50 mg: clearly efficacious in diminishing UPDRS III scores II. ZNS 50 mg: percentage of responders was markedly higher III. ZNS 50 mg and 100 mg: clearly efficacious in diminishing “OFF” time |
| Double-blind RCT | Murata et al. (2015) | Phase 3 | 16 weeks, including a 4 week run-in period | 422/354 (83.9%) | Advanced-PD patients Presence of motor complications (> 2 h “OFF” time/day) | 25, 50 mg/day or placebo | Primary: Variation in daily “OFF” time Others: Variation in UPDRS and PDQ-39 Variation in the percentage of patients with ≥ 20% reduction in “OFF” time (responders) | I. ZNS 50 mg: clearly efficacious in diminishing “OFF” time (P = 0.005, difference, −0.709 h/day) II. ZNS 50 mg: percentage of responders was markedly higher (40.5%; P < 0.001). III. ZNS 50 mg: clearly efficacious in diminishing UPDRS II (off) and UPDRS III |
| Double-blind RCT | Murata et al. (2016) Registration number: JapicCTI-101198 | Phase 3 | 14 weeks, including a 2 week run-in period | 196/166 (84.7%) | Advanced-PD patients Deterioration of response to levodopa | 25, 50 mg/day or placebo | Primary: Variation in UPDRS III scores Others: Variation in the percentage of patients with ≥ 30% reduction in UPDRS III (responders) Variation in UPDRS II scores | I. ZNS 25 mg: clearly efficacious in diminishing UPDRS III scores. (P = 0.029) II. ZNS 50 mg: percentage of responders was markedly higher (P = 0.038) III. ZNS 25 mg: clearly efficacious in diminishing UPDRS II (off) score (P = 0.039) |
Clinical trials on zonisamide effectiveness in the treatment of PD.
ZNS, zonisamide; RCT, randomized controlled trials; H-Y stage, Hoehn and Yahr stage; UPDRS, Unified Parkinson’s Disease Rating Scale; PDQ-39, Parkinson’s Disease Questionnaire-39; RBD, rapid eye movement sleep behavior disorder.
De novo/Early Stage PD
A preliminary, open-label (OL) trial () conducted in Japan suggested that a single administration of ZNS was efficacious in improving motor and sleep dysfunction in treatment-naive patients with early stage PD. Moreover, ZNS was recommended as adjunctive therapy in early stage/stable PD according to 2018 guidelines ().
Advanced-Stage PD
The largest area of the potential use of ZNS is as adjunctive therapy for motor fluctuations (). ZNS improved the motor functions and wearing-off phenomenon without worsening dyskinesia in advanced-PD patients (Murata, 2009; ). Four clinical trials by published in 2001, 2007, 2015, and 2016 Murata et al. (2001, 2007, 2015, 2016), have examined the efficacy of ZNS in 974 advanced-PD patients.
Phase 2 Trials
An OL trial on nine patients with advanced PD showed that ZNS has beneficial effects in improving the primary symptoms of PD, including motor fluctuations (Murata et al., 2001). The Unified Parkinson’s Disease Rating Scale (UPDRS) score, Hoehn and Yahr stage (H-Y stage), and “OFF” time per day were assessed after 12 weeks of ZNS treatment. Both the UPDRS score and H-Y stage (ON/OFF) improved, and unexpectedly, the duration of the “OFF” time markedly improved. These effects continued for more than a year, even for advanced-PD patients. Additionally, ZNS has a long half-life (25 mg: 90 h), and its beneficial effects could be maintained throughout a day with a single dose of the drug per day (Murata et al., 2015).
Phase 2b/3 Trials
Murata et al. (2007) conducted an RCT in Japan to assess the efficacy of a daily dose of 25, 50, and 100 mg of ZNS in 347 advanced-PD patients. ZNS 25 and 50 mg resulted in significant decreases in UPDRS III total scores from baseline (ZNS 25 mg, −6.3 ± 0.8; ZNS 50 mg, −5.8 ± 0.8, as compared with −2.0 ± 0.8 in placebo; P = 0.001 and P = 0.003, respectively; Dunnett test). Likewise, the percentage of responders, defined as patients with a reduction of ≥ 30% in UPDRS part III scores, was significantly higher with ZNS 50 mg (38.8%, P = 0.018) than with placebo (22.0%). ZNS 50 mg and ZNS 100 mg groups achieved significant improvements in reducing the total “OFF” time [the mean changes were −1.30 h (P = 0.014) and −1.63 h (P = 0.013), respectively] compared with the placebo group. Importantly, ON time with annoying dyskinesia did not increase in any ZNS group as compared with placebo; in contrast, a reduction in disabling dyskinesia was observed in the ZNS 50 mg group.
Phase 3 Trials
Two phase 3 multicenter RCTs (Murata et al., 2015, 2016) have investigated the efficacy of ZNS among 618 advanced-PD patients: the Murata et al. (2015) and Murata et al. (2016) studies.
The Murata, 2015 study (Murata et al., 2015) examined the effectiveness of ZNS in the reduction of “OFF” time in advanced-PD patients with motor fluctuation as compared with placebo. The primary endpoint was the variation in daily “OFF” time from baseline to the end of a 12-week prescription, according to diarized information at the final assessment. ZNS 50 mg met the primary endpoint and had the most significant efficacy, having a significantly longer decrease in daily “OFF” time at week 12 than placebo (ZNS 50 mg daily “OFF” time decrease: −0.719 ± 0.179 h, compared with placebo: −0.011 ± 0.173 h; P = 0.005). Moreover, the percentage of participants with a reduction in “OFF” time ≥ 20% (responders) from the beginning of treatment to week 16 was markedly higher in those receiving ZNS 50 mg than those receiving placebo (40.5% for ZNS 50 mg vs. 20.9% for placebo; P < 0.001). ZNS 50 mg also resulted in statistically significant improvements in the UPDRS II (OFF) score (P = 0.021) and UPDRS III score at week 12 vs. placebo. However, UPDRS I, UPDRS II (ON), UPDRS IV, and Parkinson’s Disease Questionnaire-39 scores did not show statistically significant differences in improvements between ZNS 50 mg and placebo. Moreover, the increase in the dyskinesia duration at week 12 was not statistically significant in those receiving ZNS 25 mg and 50 mg as compared with placebo (P = 0.103 and P = 0.235, respectively). This study demonstrated that ZNS 50 mg could significantly reduce the “OFF” time and improve the “OFF” status of activity in advanced-PD patients who exhibited the “wearing-off phenomenon.”
The Murata, 2016 study (Murata et al., 2016) explored the effectiveness and safety of ZNS 25 and 50 mg taken orally once daily, as compared with placebo. The primary endpoint was the variation from the beginning of the treatment to the final assessment in UPDRS part III scores. ZNS 25 mg met the primary endpoint at the final assessment, showing a marked reduction in UPDRS III scores than placebo at week 14 (−5.09 ± 0.9 for ZNS 25 mg vs. −2.9 ± 0.9 for placebo, P = 0.029). Likewise, ZNS 50 mg resulted in a significant reduction in UPDRS III total scores at week 12 (−6.1 ± 1.0, P = 0.049). The percentage of participants with a reduction in UPDRS III scores ≥ 30% from baseline to week 14 (responders) was markedly higher with ZNS 50 mg than with placebo (45.8% for ZNS 50 mg vs. 27.0% for placebo; P < 0.038). Furthermore, the UPDRS II (OFF) scores were significantly improved with ZNS 25 mg than with placebo (P = 0.039).
Late-Stage PD
Patients with late-stage PD (LSPD) refer to those whose H-Y stage ≥ 4 while in the “ON” time (). In a phase 2 OL study (Murata et al., 2001) by Murata, 4 of 10 patients fulfilled the LSPD definition. Two patients reached significant improvements in the UPDRS and H-Y stage, whereas the other two did not. In another two phase 3 RCTs (Murata et al., 2007, 2015), further analyses of H-Y stage 4–5 patients were not available.
For safety data of the clinical studies above, see Safety and Tolerability.
Effect on PD-Related Tremors
ZNS may have an effect on intractable tremor (; Mochio et al., 2012; Kaplan and Tarsy, 2013). A preliminary OL trial (Nakanishi et al., 2003) performed by Nakanishi et al. reported a potentially valuable role of ZNS in PD patients with residual resting tremor. Seven of nine patients (P < 0.0017) had a decrease in the scale of tremor with ZNS administration. also reported a case where ZNS was efficacious against re-emergent and residual resting tremor in PD. Both re-emergent and intractable resting tremors markedly decreased with a dosage of 100 mg/day. ZNS was well-tolerated, although mild sleepiness was observed. As previously suggested, ZNS had a beneficial effect on essential tremor (ET) (Ondo, 2006, 2007; Zesiewicz et al., 2007; ). Another study conducted by Bermejo et al. suggested that ZNS was beneficial to patients with comorbid ET and PD (). In fact, ZNS is effective in controlling symptoms of both disorders. ZNS could thus be a good therapeutic option as adjunctive therapy in PD-related tremor ().
Effects on Non-motor Symptoms
Impulsive–Compulsive Disorders
Impulse control behaviors (ICBs) belong to impulsive–compulsive disorders, which are associated with dopamine replacement therapy in PD (; Raja and Bentivoglio, 2012). Recently, Kon et al. (2018) found that patients who developed ICB at final evaluation were prescribed ZNS earlier and at a higher dosage than other patients, suggesting that ZNS may be associated with ICB. In another study, ZNS increased novelty-seeking behaviors in mice, which were risk factors for ICB (Voon et al., 2011; Uemura et al., 2017). Thus, ZNS might be related to the development of impulsive–compulsive disorders (ICDs) in PD. However, an OL trial () performed by Bermejo et al. suggested that ZNS could play an essential positive role in ICDs. The severity of ICBs was significantly reduced, from −5.8 to −4.8 (mean change). It is important that further RCTs estimate the effectiveness of ZNS on ICDs in patients with PD.
Rapid Eye Movement Sleep Behavior Disorder
Rapid eye movement sleep behavior disorder (RBD) is considered one of the most prevailing non-motor symptoms in PD patients (Mollenhauer et al., 2016). It may occur several years before the first symptoms of PD or during the progression of PD (). Recently, Kataoka and Ueno (2012) reported a case in which treatment with ZNS resolved dream-enacting behaviors and vivid nightmares in an early stage PD patient, suggesting that ZNS might be efficacious for the management of RBD. Further studies are required to estimate the effectiveness of ZNS on RBD in early- and advanced-stage PD patients.
Dementia
Dementia is described as an essential complication in PD (Iwaki et al., 2019). Iwaki et al. (2019) and Murata et al. (2007) demonstrated that ZNS may reduce the development of cognitive impairment better than other antiparkinsonian drugs. Although the vast majority of trials were performed in the Japanese population, Tombini et al. (2013) reported the case of a 78 years old Caucasian male patient with PD and dementia, who later developed epilepsy. ZNS significantly improved his seizure and extrapyramidal symptoms without affecting his cognitive status. Further RCTs are needed to evaluate the efficacy of ZNS in preventing cognitive decline among PD patients of different ethnicities (; Tombini et al., 2013).
Safety and Tolerability
Generally, the therapeutic dose of ZNS for epilepsy (300–600 mg/day) is much higher than that needed for PD (; Ohtahara, 2006). We believe that ZNS is a safe treatment for PD as it has been applied for seizures in Japan for more than 30 years and is well-tolerated.
By now, ZNS has been prescribed to 974 PD patients in four clinical trials by Murata et al. (2001, 2007, 2015, 2016) these studies have suggested that ZNS has high safety without a dose-response relationship for common adverse events. Incidences of adverse events associated with ZNS treatment are summarized in Table 3.
TABLE 3
| Side effects | Phase 3 trials (Murata et al., 2015) | Phase 3 trials (Murata et al., 2016) | Phase 2b/3 trials (Murata et al., 2007) | |||||||||
| PLC | ZNS 25 mg | ZNS 50 mg | Total | PLC | ZNS 25 mg | ZNS 50 mg | PLC | ZNS 25 mg | ZNS 50 mg | ZNS 100 mg | Total | |
| Total | 49.6% | 57.7% | 60.9% | 59.3% | 65.1% | 55.6% | 60.3% | 65.1% | 70.9% | 72.9% | 79.5% | / |
| Constipation | 1.5% | 1.5% | 3.1% | 2.3% | 6.3% | 1.6% | 1.6% | 3.6% | 6.3% | 8.2% | 4.8% | 6.5% |
| Nasopharyngitis | 6.9% | 7.7% | 3.9% | 5.8% | 11.1% | 4.8% | 3.2% | / | / | / | / | / |
| Bronchitis | 2.3% | 1.5% | 3.1% | 2.3% | / | / | / | / | / | / | / | / |
| Contusion | 3.1% | 2.3% | 1.6% | 1.9% | / | / | / | / | / | / | / | / |
| Blood LDH increased | 3.1% | 2.3% | 3.1% | 2.7% | / | / | / | / | / | / | / | / |
| Blood urea increased | 1.5% | 3.1% | 0.8% | 1.9% | / | / | / | / | / | / | / | / |
| Decreased appetite | 3.1% | 4.6% | 0.8% | 2.7% | 6.3% | 4.8% | 1.6% | 14.5% | 5.1% | 8.2% | 16.9% | 10.1% |
| Dyskinesia | 7.6% | 6.9% | 7.0% | 7.0% | 1.6% | 8.2% | 3.2% | / | / | / | / | / |
| Somnolence | 2.3% | 3.1% | 6.3% | 4.7% | / | / | / | 4.8% | 1.3% | 15.3% | 15.7% | 10.9% |
| Insomnia | 3.1% | 3.1% | 0.0% | 1.6% | 7.9% | 4.8% | 4.8% | / | / | / | / | / |
| Apathy | / | / | / | / | / | / | / | 6.0% | 7.6% | 7.1% | 10.8% | 8.5% |
| Dizziness | / | / | / | / | / | / | / | 7.2% | 3.8% | 5.9% | 7.2% | 5.7% |
| Weight loss | / | / | / | / | 6.3% | 0% | 4.8% | 4.8% | 7.6% | 3.5% | 9.6% | 6.9% |
| Increased in serum CK | / | / | / | / | 6.3% | 4.8% | 1.6% | 8.4% | 8.9% | 8.2% | 4.8% | 7.3% |
Side effects related to ZNS therapy that appear in more than 3% of participants.
Only data for adverse effects with an incidence of > 5% were reported in phase 3 trials (Murata et al., 2016) and phase 2b/3 trials (Murata et al., 2007). Adverse events affecting > 5% are in bold font. ZNS, zonisamide; PLC, placebo; LDH, lactate dehydrogenase; CK, creatinine phosphokinase; /, not reported.
In a phase 2 trial, the reported side effects were dry mouth (n = 1) and the exaggeration of dyskinesia (n = 4) (Murata et al., 2001). Notably, doses of ZNS in that study were as high as 50–300 mg/day, and the exaggeration of dyskinesia could disappear with a reduction of levodopa dosage.
In a phase 2b/3 trial, the most frequently reported adverse effects in the total ZNS group, as compared with placebo, were apathy (8.5%), constipation (6.5%), weight loss (6.9%), and somnolence (10.9%) (Murata et al., 2007). Although the incidences of some adverse events for ZNS 50 mg and 100 mg were higher than those for the placebo, there were no statistical differences in the incidences of dyskinesia and hallucination, which are both mostly observed adverse effects of antiparkinsonian drugs, between ZNS groups and placebo, indicating that ZNS is well-tolerated in PD patients at doses of 25–100 mg/day.
In the phase 3 Murata et al. (2015) trial, ZNS 25 mg and 50 mg were well-tolerated in PD patients (Murata et al., 2015). The incidences of total adverse events reported in ZNS 25 mg (57.7%) and 50 mg (60.9%) were not statistically different from those in placebo (49.6%; P > 0.05). The incidence of somnolence and that of constipation for ZNS 50 mg were higher than that for placebo (somnolence: 2.3% for placebo, 3.1% for ZNS 25 mg, 6.3% for ZNS 50 mg; constipation: 1.5, 1.5, and 3.1%, respectively). Hallucination and dyskinesia did not occur more frequently for ZNS 25 mg or 50 mg than for placebo.
In the phase 3 Murata et al. (2016) trial, ZNS 25 mg and 50 mg were also well-tolerated in PD patients (Murata et al., 2016). The incidences of adverse events reported in the ZNS 25 mg (55.6%) and 50 mg (60.3%) groups were not statistically different from that in placebo (65.1%; P = 0.363 and P = 0.713, respectively). The incidence of adverse events that occurred in more than 5% of participants was similar in all three groups. As in the Murata et al. (2015) study, dyskinesia and hallucination did not occur more frequently in ZNS 25 and 50 mg compared with placebo. The incidences of abnormal changes in vital signs, 12-lead resting electrocardiogram, and laboratory tests were low in all groups.
Moreover, a large-scale study in Japan compared ZNS with other antiparkinsonian drugs by analyzing the associations between the administration of eight different varieties of antiparkinsonian drugs and the incidence of PD-relevant symptoms (Iwaki et al., 2019). Iwaki et al. conducted this study based on real-world data from Japan for 2008 to 2014. They demonstrated that ZNS had lower incidences of insomnia, gastric ulcers, and dementia than three of seven other anti-PD drugs (P < 0.05).
It is important that medical doctors should remember to ask patients about sulfa-allergies before prescribing ZNS because it is a sulfonamide (Yang and Perry, 2009).
Discussion
The sulfonamide ZNS exhibits both dopaminergic and non-dopaminergic mechanisms. It is a T-type calcium-channel antagonist and a reversible MAO-B inhibitor. It could modulate levodopa-dopamine metabolism and expression of various receptors. Most importantly, it has the potential for neuroprotection via various mechanisms, such as modulation of dopamine turnover, induction of neurotrophic factors, inhibition of oxidative stress and apoptosis, inhibition of neuroinflammation, modulation of synaptic transmission, and modulation of gene expression. ZNS has a dose-dependent pharmacokinetic profile and has high bioavailability. It interacts with CYP3A4.
The current studies show that ZNS is effective and safe at 25–50 mg/day as an adjunctive therapy in patients with PD. Given the general beneficial effect and safety profile, we recommend initiating this drug at 25 mg/day and titrating it to 50 mg/day when needed. ZNS 50 mg could reduce the “OFF” time, while not increasing troublesome dyskinesia in PD patients with the “wearing-off phenomenon.” ZNS is well-tolerated, with few associated adverse events.
There are still a few limitations in the administration of ZNS. The vast majority of clinical trials of ZNS have been conducted in Japan, and the antiparkinsonian mechanism of ZNS remains incompletely clarified. Further RCTs are needed to estimate the effectiveness of ZNS in PD patients of different ethnicities. Moreover, further in-depth research on the antiparkinsonian mechanism of ZNS is needed.
Statements
Author contributions
CL carried out the literature retrieval, wrote the manuscript, and made the tables and figures. LX, YL, ZY, and SC critically modified the manuscript. AX funded this project, critically modified the manuscript, and supervised this work. All authors have seen and approved the final version of the manuscript.
Funding
This work was funded by the grants from the National Natural Science Foundation of China (No. 81971192).
Acknowledgments
We would like to thank Editage (www.editage.com) for English language editing.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AlborghettiM.NicolettiF. (2019). Different generations of Type-B monoamine oxidase inhibitors in parkinson’s disease: from bench to bedside.Curr. Neuropharmacol.17861–873. 10.2174/1570159x16666180830100754
2
ArawakaS.FukushimaS.SatoH.SasakiA.KogaK.KoyamaS.et al (2014). Zonisamide attenuates alpha-synuclein neurotoxicity by an aggregation-independent mechanism in a rat model of familial Parkinson’s disease.PLoS One9:e89076. 10.1371/journal.pone.0089076
3
ArzimanoglouA.RahbaniA. (2006). Zonisamide for the treatment of epilepsy.Expert Rev. Neurother.61283–1292. 10.1586/14737175.6.9.1283
4
AsanumaM.MiyazakiI.Diaz-CorralesF. J.KimotoN.KikkawaY.TakeshimaM.et al (2010). Neuroprotective effects of zonisamide target astrocyte.Ann. Neurol.67239–249. 10.1002/ana.21885
5
AsanumaM.MiyazakiI.Diaz-CorralesF. J.MiyoshiK.OgawaN.MurataM. (2008). Preventing effects of a novel anti-parkinsonian agent zonisamide on dopamine quinone formation.Neurosci. Res.60106–113. 10.1016/j.neures.2007.10.002
6
BenteaE.Van LiefferingeJ.VerbruggenL.MartensK.KobayashiS.DeneyerL.et al (2017). Zonisamide attenuates lactacystin-induced parkinsonism in mice without affecting system xc.Exp. Neurol.29015–28. 10.1016/j.expneurol.2016.12.009
7
BermejoP. E. (2007). Zonisamide in patients with essential tremor and Parkinson’s disease.Mov. Disord.222137–2138. 10.1002/mds.21717
8
BermejoP. E.AncionesB. (2009). A review of the use of zonisamide in Parkinson’s disease.Ther. Adv. Neurol. Disord.2313–317. 10.1177/1756285609338501
9
BermejoP. E.Ruiz-HueteC.AncionesB. (2010). Zonisamide in managing impulse control disorders in Parkinson’s disease.J. Neurol.2571682–1685. 10.1007/s00415-010-5603-7
10
BermejoP. E.Ruiz-HueteC.DoradoR.AncionesB. (2008). [Zonisamide in refractory essential tremor].Rev. Neurol.46139–142.
11
BonuccelliU.Del DottoP. (2006). New pharmacologic horizons in the treatment of Parkinson disease.Neurology67(7 Suppl. 2), S30–S38. 10.1212/wnl.67.7_suppl_2.s30
12
ChaP. C.SatakeW.Ando-KanagawaY.YamamotoK.MurataM.TodaT. (2020). Genome-wide association study identifies zonisamide responsive gene in Parkinson’s disease patients.J. Hum. Genet.65693–704. 10.1038/s10038-020-0760-8
13
ChenJ. J.SwopeD. M. (2007). Pharmacotherapy for Parkinson’s disease.Pharmacotherapy27(12 Pt 2), 161S–173S. 10.1592/phco.27.12part2.161S
14
ChoudhuryM. E.MoritoyoT.KuboM.KyawW. T.YabeH.NishikawaN.et al (2011). Zonisamide-induced long-lasting recovery of dopaminergic neurons from MPTP-toxicity.Brain Res.1384170–178. 10.1016/j.brainres.2011.02.017
15
ChoudhuryM. E.SugimotoK.KuboM.IwakiH.TsujiiT.KyawW. T.et al (2012). Zonisamide up-regulated the mRNAs encoding astrocytic anti-oxidative and neurotrophic factors.Eur. J. Pharmacol.68972–80. 10.1016/j.ejphar.2012.05.012
16
ClaassenD. O.JosephsK. A.AhlskogJ. E.SilberM. H.Tippmann-PeikertM.BoeveB. F. (2010). REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century.Neurology75494–499. 10.1212/WNL.0b013e3181ec7fac
17
CondelloS.CurroM.FerlazzoN.CostaG.VisalliG.CaccamoD.et al (2013). Protective effects of zonisamide against rotenone-induced neurotoxicity.Neurochem. Res.382631–2639. 10.1007/s11064-013-1181-2
18
CopelandC. S.NealeS. A.SaltT. E. (2013). Actions of Xanthurenic acid, a putative endogenous Group II metabotropic glutamate receptor agonist, on sensory transmission in the thalamus.Neuropharmacology66133–142. 10.1016/j.neuropharm.2012.03.009
19
CostaC.TozziA.LuchettiE.SiliquiniS.BelcastroV.TantucciM.et al (2010). Electrophysiological actions of zonisamide on striatal neurons: selective neuroprotection against complex I mitochondrial dysfunction.Exp. Neurol.221217–224. 10.1016/j.expneurol.2009.11.002
20
de LauL. M. L.BretelerM. M. B. (2006). Epidemiology of Parkinson’s disease.Lancet Neurol.5525–535. 10.1016/S1474-4422(06)70471-9
21
EvansA. H.PaveseN.LawrenceA. D.TaiY. F.AppelS.DoderM.et al (2006). Compulsive drug use linked to sensitized ventral striatal dopamine transmission.Ann. Neurol.59852–858. 10.1002/ana.20822
22
FabbriM.FerreiraJ. J.LeesA.StocchiF.PoeweW.TolosaE.et al (2018). Opicapone for the treatment of Parkinson;’s disease: a review of a new licensed medicine.Mov. Disord.331528–1539. 10.1002/mds.27475
23
FazioF.LionettoL.MolinaroG.BertrandH. O.AcherF.NgombaR. T.et al (2012). Cinnabarinic acid, an endogenous metabolite of the kynurenine pathway, activates type 4 metabotropic glutamate receptors.Mol. Pharmacol.81643–656. 10.1124/mol.111.074765
24
FoxS. H. (2013). Non-dopaminergic treatments for motor control in Parkinson’s disease.Drugs731405–1415. 10.1007/s40265-013-0105-4
25
FoxS. H.KatzenschlagerR.LimS. Y.BartonB.de BieR. M. A.SeppiK.et al (2018). International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson’s disease.Mov. Disord.331248–1266. 10.1002/mds.27372
26
FreedC. R.GreeneP. E.BreezeR. E.TsaiW. Y.DuMouchelW.KaoR.et al (2001). Transplantation of embryonic dopamine neurons for severe Parkinson’s disease.N. Engl. J. Med.344710–719. 10.1056/nejm200103083441002
27
FreitasM. E.FoxS. H. (2016). Nondopaminergic treatments for Parkinson’s disease: current and future prospects.Neurodegener. Dis. Manag.6249–268. 10.2217/nmt-2016-0005
28
FukuyamaK.TanahashiS.HoshikawaM.ShinagawaR.OkadaM. (2014). Zonisamide regulates basal ganglia transmission via astroglial kynurenine pathway.Neuropharmacology76(Pt A), 137–145. 10.1016/j.neuropharm.2013.08.002
29
GluckM. R.SantanaL. A.GransonH.YahrM. D. (2004). Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson’s activity.J. Neural Transm.111713–724. 10.1007/s00702-004-0107-1
30
GreenamyreJ. T.HastingsT. G. (2004). Biomedicine. Parkinson’s–divergent causes, convergent mechanisms.Science3041120–1122. 10.1126/science.1098966
31
GroverN. D.LimayeR. P.GokhaleD. V.PatilT. R. (2013). Zonisamide: a review of the clinical and experimental evidence for its use in Parkinson’s disease.Indian J. Pharmacol.45547–555. 10.4103/0253-7613.121266
32
HargusG.CooperO.DeleidiM.LevyA.LeeK.MarlowE.et al (2010). Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats.Proc. Natl. Acad, Sci. U.S.A.10715921–15926. 10.1073/pnas.1010209107
33
HossainM. M.WeigB.ReuhlK.GearingM.WuL. J.RichardsonJ. R. (2018). The anti-parkinsonian drug zonisamide reduces neuroinflammation: role of microglial Nav 1.6.Exp. Neurol.308111–119. 10.1016/j.expneurol.2018.07.005
34
IijimaM.OsawaM.KobayashiM.UchiyamaS. (2011). Efficacy of zonisamide in a case of Parkinson’s disease with intractable resting and re-emergent tremor.Eur. J. Neurol.18e43–e44. 10.1111/j.1468-1331.2010.03276.x
35
IkedaK.HanashiroS.SawadaM.IwasakiY. (2015). Preliminary study of zonisamide monotherapy in de novo patients with early Parkinson’s disease.Neurolo. Clin. Neurosci.3163–166. 10.1111/ncn3.179
36
IkedaK.YanagihashiM.MiuraK.IshikawaY.HirayamaT.TakazawaT.et al (2018). Zonisamide cotreatment delays striatal dopamine transporter reduction in Parkinson disease: a retrospective, observational cohort study.J. Neurol. Sci.3915–9. 10.1016/j.jns.2018.05.013
37
ItoT.YamaguchiT.MiyazakiH.SekineY.ShimizuM.IshidaS.et al (1982). Pharmacokinetic studies of AD-810, a new antiepileptic compound. Phase I trials.Arzneimittelforschung321581–1586.
38
IwakiH.TagawaM.IwasakiK.KawakamiK.NomotoM. (2019). Comparison of zonisamide with non-levodopa, anti-Parkinson’s disease drugs in the incidence of Parkinson’s disease-relevant symptoms.J. Neurol. Sci.402145–152. 10.1016/j.jns.2019.05.028
39
JanszkyJ. (2009). [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases].Ideggyogy. Sz.62383–389.
40
KaplanS.TarsyD. (2013). Initial treatment of Parkinson’s disease: an update.Curr. Treatm. Opt. Neurol.15377–384. 10.1007/s11940-013-0236-7
41
KataokaH.UenoS. (2012). Nightmare-enacting behavior responding to zonisamide in early Parkinson’s disease.Case Rep. Neurol.431–33. 10.1159/000336441
42
KawajiriS.MachidaY.SaikiS.SatoS.HattoriN. (2010). Zonisamide reduces cell death in SH-SY5Y cells via an anti-apoptotic effect and by upregulating MnSOD.Neurosci. Lett.48188–91. 10.1016/j.neulet.2010.06.058
43
KonT.UenoT.HagaR.TomiyamaM. (2018). The factors associated with impulse control behaviors in Parkinson’s disease: a 2-year longitudinal retrospective cohort study.Brain Behav.8:e01036. 10.1002/brb3.1036
44
KunisawaN.ShimizuS.KatoM.IhaH. A.IwaiC.HashimuraM.et al (2018). Pharmacological characterization of nicotine-induced tremor: responses to anti-tremor and anti-epileptic agents.J. Pharmacol. Sci.137162–169. 10.1016/j.jphs.2018.05.007
45
LewM. (2007). Overview of Parkinson’s disease.Pharmacotherapy27(12 Pt 2), 155S–160S. 10.1592/phco.27.12part2.155S
46
LiuY.ZhangY.ZhuK.ChiS.WangC.XieA. (2020). Emerging role of sirtuin 2 in Parkinson’s disease.Front. Aging Neurosci.11:372. 10.3389/fnagi.2019.00372
47
MatsumotoK.MiyazakiH.FujiiT.KagemotoA.MaedaT.HashimotoM. (1983). Absorption, distribution and excretion of 3-(sulfamoyl[14C]methyl)-1,2-benziosoxazole (AD-810) in Rats, Dogs and Monkeys and of AD-810 in Men.Arzneimittelforschung33961–968.
48
MatsunagaS.KishiT.IwataN. (2017). Combination therapy with zonisamide and antiparkinson drugs for parkinson’s disease: a meta-analysis.J. Alzheimer’s Dis.561229–1239. 10.3233/jad-161068
49
MendezI.Sanchez-PernauteR.CooperO.ViñuelaA.FerrariD.BjörklundL.et al (2005). Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson’s disease.Brain128(Pt 7), 1498–1510. 10.1093/brain/awh510
50
MiwaH. (2007). Zonisamide for the treatment of Parkinson’s disease.Expert Rev. Neurother.71077–1083. 10.1586/14737175.7.9.1077
51
MochioS.SengokuR.KonoY.MoritaM.MitsumuraH.TakagiS.et al (2012). Actigraphic study of tremor before and after treatment with zonisamide in patients with Parkinson’s disease.Parkinsonism Relat. Disord.18906–908. 10.1016/j.parkreldis.2012.04.007
52
MollenhauerB.ZimmermannJ.Sixel-DoringF.FockeN. K.WickeT.EbentheuerJ.et al (2016). Monitoring of 30 marker candidates in early Parkinson disease as progression markers.Neurology87168–177. 10.1212/WNL.0000000000002651
53
MoritaS.MiwaH.KondoT. (2005). Effect of zonisamide on essential tremor: a pilot crossover study in comparison with arotinolol.Parkinsonism Relat. Disorde.11101–103. 10.1016/j.parkreldis.2004.09.004
54
MurataM. (2004). Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson’s disease.Curr. Pharm. Des.10687–693. 10.2174/1381612043453180
55
MurataM. (2009). [Pharmacologic treatment of Parkinson disease].Brain Nerve61464–472.
56
MurataM.HasegawaK.KanazawaI. (2007). Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study.Neurology6845–50. 10.1212/01.wnl.0000250236.75053.16
57
MurataM.HasegawaK.KanazawaI.FukasakaJ.KochiK.ShimazuR. (2015). Zonisamide improves wearing-off in Parkinson’s disease: a randomized, double-blind study.Mov. Disord.301343–1350. 10.1002/mds.26286
58
MurataM.HasegawaK.KanazawaI.ShirakuraK.KochiK.ShimazuR. (2016). Randomized placebo-controlled trial of zonisamide in patients with Parkinson’s disease.Neurol. Clin. Neurosci.410–15. 10.1111/ncn3.12026
59
MurataM.HoriuchiE.KanazawaI. (2001). Zonisamide has beneficial effects on Parkinson’s disease patients.Neurosci. Res.41397–399. 10.1016/s0168-0102(01)00298-x
60
NakanishiI.KohmotoJ.MiwaH.KondoT. (2003). [Effect of zonisamide on resting tremong tremor resistant to antiparkinsonian medication].No Shinkei55685–689.
61
NakasaH.NakamuraH.OnoS.TsutsuiM.KiuchiM.OhmoriS.et al (1998). Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data.Eur. J. Clin. Pharmacol.54177–183. 10.1007/s002280050442
62
NishijimaH.MikiY.UenoS.TomiyamaM. (2018). Zonisamide enhances motor effects of levodopa. Not of apomorphine, in a rat model of Parkinson’s Disease.Parkinson’s Dis.2018:8626783. 10.1155/2018/8626783
63
OhmoriS.NakasaH.AsanomeK.KuroseY.IshiiI.HosokawaM.et al (1998). Differential catalytic properties in metabolism of endogenous and exogenous substrates among CYP3A enzymes expressed in COS-7 cells.Biochim. Biophys. Acta1380297–304. 10.1016/s0304-4165(97)00156-6
64
OhtaharaS. (2006). Zonisamide in the management of epilepsy–Japanese experience.Epilepsy Res.68(Suppl. 2), S25–S33. 10.1016/j.eplepsyres.2005.11.007
65
OkadaM.KanekoS.HiranoT.MizunoK.KondoT.OtaniK.et al (1995). Effects of zonisamide on dopaminergic system.Epilepsy Res.22193–205. 10.1016/0920-1211(95)00078-x
66
OkiM.KanekoS.MoriseS.TakenouchiN.HashizumeT.TsugeA.et al (2017). Zonisamide ameliorates levodopa-induced dyskinesia and reduces expression of striatal genes in Parkinson model rats.Neurosci. Res.12245–50. 10.1016/j.neures.2017.04.003
67
OlanowC. W.GoetzC. G.KordowerJ. H.StoesslA. J.SossiV.BrinM. F.et al (2003). A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease.Ann. Neurol.54403–414. 10.1002/ana.10720
68
OmuraT.AsariM.YamamotoJ.KamiyamaN.OkaK.HoshinaC.et al (2012). HRD1 levels increased by zonisamide prevented cell death and caspase-3 activation caused by endoplasmic reticulum stress in SH-SY5Y cells.J. Mol. Neurosci.46527–535. 10.1007/s12031-011-9638-8
69
OmuraT.KanekoM.OkumaY.MatsubaraK.NomuraY. (2013). Endoplasmic reticulum stress and Parkinson’s disease: the role of HRD1 in averting apoptosis in neurodegenerative disease.Oxid. Med. Cell. Longev.2013:239854. 10.1155/2013/239854
70
OndoW. G. (2006). Essential tremor: treatment options.Curr. Treatm. Opt. Neurol.8256–267. 10.1007/s11940-006-0016-8
71
OndoW. G. (2007). Zonisamide for essential tremor.Clin. Neuropharmacol.30345–349. 10.1097/WNF.0b013e318074dd4f
72
RajaM.BentivoglioA. R. (2012). Impulsive and compulsive behaviors during dopamine replacement treatment in Parkinson’s Disease and other disorders.Curr. Drug Saf.763–75. 10.2174/157488612800492726
73
RheeY.-H.KoJ.-Y.ChangM.-Y.YiS.-H.KimD.KimC.-H.et al (2011). Protein-based human ips cells efficiently generate functional dopamine neurons and can treat a rat model of parkinson disease.J. Clin. Invest.1212326–2335. 10.1172/JCI45794
74
RoslerT. W.Arias-CarrionO.HoglingerG. U. (2010). Zonisamide: aspects in neuroprotection.Exp. Neurol.224336–339. 10.1016/j.expneurol.2010.04.017
75
SanoH.ChikenS.HikidaT.KobayashiK.NambuA. (2013). Signals through the striatopallidal indirect pathway stop movements by phasic excitation in the substantia nigra.J. Neurosci.337583–7594. 10.1523/JNEUROSCI.4932-12.2013
76
SanoH.MurataM.NambuA. (2015). Zonisamide reduces nigrostriatal dopaminergic neurodegeneration in a mouse genetic model of Parkinson’s disease.J. Neurochem.134371–381. 10.1111/jnc.13116
77
SanoH.NambuA. (2019). The effects of zonisamide on L-DOPA-induced dyskinesia in Parkinson’s disease model mice.Neurochem. Int.124171–180. 10.1016/j.neuint.2019.01.011
78
SantosC. M. (2012). New agents promote neuroprotection in Parkinson’s disease models.CNS Neurol. Disord. Drug Targets11410–418. 10.2174/187152712800792820
79
SchapiraA. H. (2007). Treatment options in the modern management of Parkinson disease.Arch. Neurol.641083–1088. 10.1001/archneur.64.8.1083
80
SiebertG. A.PondS. M.Bryan-LlukaL. J. (2000). Further characterisation of the interaction of haloperidol metabolites with neurotransmitter transporters in rat neuronal cultures and in transfected COS-7 cells.Naunyn Schmiedeberg’s Arch. Pharmacol.361255–264. 10.1007/s002109900202
81
SillsG.BrodieM. (2007). Pharmacokinetics and drug interactions with zonisamide.Epilepsia48435–441. 10.1111/j.1528-1167.2007.00983.x
82
SonsallaP. K.WongL. Y.WinnikB.BuckleyB. (2010). The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance.Exp. Neurol.221329–334. 10.1016/j.expneurol.2009.11.018
83
StiffD. D.RobicheauJ. T.ZemaitisM. A. (1992). Reductive metabolism of the anticonvulsant agent zonisamide, a 1,2-benzisoxazole derivative.Xenobiotica221–11. 10.3109/00498259209053097
84
TachibanaY.KitaH.ChikenS.TakadaM.NambuA. (2008). Motor cortical control of internal pallidal activity through glutamatergic and GABAergic inputs in awake monkeys.Eur. J. Neurosci.27238–253. 10.1111/j.1460-9568.2007.05990.x
85
TombiniM.PellegrinoG.Di PinoG.AssenzaG. (2013). Zonisamide for seizures in Parkinson’s disease with dementia.Seizure22324–325. 10.1016/j.seizure.2013.01.011
86
TsujiiS.IshisakaM.HaraH. (2015a). Modulation of endoplasmic reticulum stress in Parkinson’s disease.Eur. J. Pharmacol.765154–156. 10.1016/j.ejphar.2015.08.033
87
TsujiiS.IshisakaM.ShimazawaM.HashizumeT.HaraH. (2015b). Zonisamide suppresses endoplasmic reticulum stress-induced neuronal cell damage in vitro and in vivo.Eur. J. Pharmacol.746301–307. 10.1016/j.ejphar.2014.09.023
88
UedaY.TokashikiS.KanemaruA.KojimaT. (2012). Effect of zonisamide co-administration with levodopa on global gene expression in the striata of rats with Parkinson’s disease.Biochem. Biophys. Res. Commun.428401–404. 10.1016/j.bbrc.2012.10.067
89
UemuraM. T.AsanoT.HikawaR.YamakadoH.TakahashiR. (2017). Zonisamide inhibits monoamine oxidase and enhances motor performance and social activity.Neurosci. Res.12425–32. 10.1016/j.neures.2017.05.008
90
UenoS. I.SaikiS.FujimakiM.Takeshige-AmanoH.HatanoT.OyamaG.et al (2018). Zonisamide administration improves fatty acid beta-oxidation in Parkinson’s Disease.Cells8:14. 10.3390/cells8010014
91
UnoH.KurokawaM.MasudaY.NishimuraH. (1979). Studies on 3-substituted 1,2-benzisoxazole derivatives. 6. Syntheses of 3-(sulfamoylmethyl)-1,2-benzisoxazole derivatives and their anticonvulsant activities.J. Med. Chem.22180–183. 10.1021/jm00188a011
92
VoonV.SohrM.LangA. E.PotenzaM. N.SiderowfA. D.WhetteckeyJ.et al (2011). Impulse control disorders in Parkinson disease: a multicenter case–control study.Ann. Neurol.69986–996. 10.1002/ana.22356
93
WangL.KitaiS. T.XiangZ. (2006). Activity-dependent bidirectional modification of inhibitory synaptic transmission in rat subthalamic neurons.J. Neurosci.267321–7327. 10.1523/JNEUROSCI.4656-05.2006
94
WichmannT.DeLongM. R. (2006). Basal ganglia discharge abnormalities in Parkinson’s disease.J. Neural Transm. Suppl.7021–25. 10.1007/978-3-211-45295-0_5
95
WillmoreL. J. (2005). Antiepileptic drugs and neuroprotection: current status and future roles.Epilepsy Behav.7(Suppl. 3), S25–S28. 10.1016/j.yebeh.2005.08.006
96
YagiH.OhkawaraB.NakashimaH.ItoK.TsushimaM.IshiiH.et al (2015). Zonisamide enhances neurite elongation of primary motor neurons and facilitates peripheral nerve regeneration in vitro and in a mouse model.PLoS One10:e0142786. 10.1371/journal.pone.0142786
97
YamamuraS.OhoyamaK.NagaseH.OkadaM. (2009). Zonisamide enhances delta receptor-associated neurotransmitter release in striato-pallidal pathway.Neuropharmacology57322–331. 10.1016/j.neuropharm.2009.05.005
98
YangL. P.PerryC. M. (2009). Zonisamide: in Parkinson’s disease.CNS Drugs23703–711. 10.2165/00023210-200923080-00007
99
YangY. C.TaiC. H.PanM. K.KuoC. C. (2014). The T-type calcium channel as a new therapeutic target for Parkinson’s disease.Pflugers Arch.466747–755. 10.1007/s00424-014-1466-6
100
YanoR.YokoyamaH.KuroiwaH.KatoH.ArakiT. (2009). A novel anti-Parkinsonian agent, zonisamide, attenuates MPTP-induced neurotoxicity in mice.J. Mol. Neurosci.39211–219. 10.1007/s12031-009-9181-z
101
YokoyamaH.YanoR.KuroiwaH.TsukadaT.UchidaH.KatoH.et al (2010). Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.Metab. Brain Dis.25135–143. 10.1007/s11011-010-9191-0
102
YoshikawaT.SamataB.OguraA.MiyamotoS.TakahashiJ. (2013). Systemic administration of valproic acid and zonisamide promotes differentiation of induced pluripotent stem cell-derived dopaminergic neurons.Front. Cell. Neurosci.7:11. 10.3389/fncel.2013.00011
103
YurekliV. A.GurlerS.NazirogluM.UguzA. C.KoyuncuogluH. R. (2013). Zonisamide attenuates MPP+-induced oxidative toxicity through modulation of Ca2+ signaling and caspase-3 activity in neuronal PC12 cells.Cell. Mol. Neurobiol.33205–212. 10.1007/s10571-012-9886-3
104
ZesiewiczT. A.WardC. L.HauserR. A.Sanchez-RamosJ.StaffettiJ. F.SullivanK. L. (2007). A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor.Mov. Disord.22279–282. 10.1002/mds.21282
Summary
Keywords
Parkinson’s disease, zonisamide, mechanism, neuroprotection, motor fluctuations, non-motor symptoms, antiparkinsonian drug, pharmacokinetics
Citation
Li C, Xue L, Liu Y, Yang Z, Chi S and Xie A (2020) Zonisamide for the Treatment of Parkinson Disease: A Current Update. Front. Neurosci. 14:574652. doi: 10.3389/fnins.2020.574652
Received
20 June 2020
Accepted
20 November 2020
Published
21 December 2020
Volume
14 - 2020
Edited by
Anna R. Carta, University of Cagliari, Italy
Reviewed by
Wladyslaw-Lason, Polish Academy of Sciences (IF PAS), Poland; Thiago Cardoso Vale, Juiz de Fora Federal University, Brazil
Updates
Copyright
© 2020 Li, Xue, Liu, Yang, Chi and Xie.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Anmu Xie, xieanmu@163.com
This article was submitted to Neuropharmacology, a section of the journal Frontiers in Neuroscience
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.